---
schema_version: "secwatch.filing_event.v1"
accession: "0000784199-22-000122"
form_type: "8-K"
ticker: "AORT"
cik: "0000784199"
company_name: "ARTIVION, INC."
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-26T00:08:53.622635+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Artivion Q1 revenue up 8.6% to $77.2M; net loss of $0.08 per share

## Summary
- Revenue $77.2M, +8.6% GAAP YoY; constant currency growth 11.2% driven by aortic stent grafts (+34%) and On-X (+11%).
- Net loss $3.4M ($0.08/share) vs $3.1M loss in Q1 2021; non-GAAP net income $1.1M ($0.03/share) vs $1.4M.
- Asia Pacific constant currency revenue +39%; Latin America +93%. Pipeline progress: PROACT Mitral and PerClot FDA PMA expected in 2022.
- FY 2022 constant currency revenue growth guidance reaffirmed at 9.0%-11.0%.

## SEC filing metadata
- accession: 0000784199-22-000122
- form_type: 8-K
- ticker: AORT
- cik: 0000784199
- company_name: ARTIVION, INC.
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/784199/000078419922000122/0000784199-22-000122-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/784199/000078419922000122/aort-20220505x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000784199-22-000122
- JSON: https://secwatch.observer/filing/0000784199-22-000122.json
- Plain text: https://secwatch.observer/filing/0000784199-22-000122.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.